Microbot Medical Inc. (NASDAQ:MBOT) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have been given an average rating of “Moderate Buy” by the seven brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $5.08.

Several equities analysts have weighed in on the stock. Wall Street Zen lowered shares of Microbot Medical from a “sell” rating to a “strong sell” rating in a report on Saturday, October 24th. Zacks Research lowered shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Microbot Medical in a report on Wednesday, October 21st. UBS Group set a $2.50 price objective on Microbot Medical in a research report on Friday, October 23rd. Finally, B. Riley Financial initiated coverage on Microbot Medical in a research report on Friday, September 11th. They issued a “buy” rating and a $4.00 target price on the stock.

Microbot Medical Trading Up 5.7%

Shares of NASDAQ MBOT opened at $1.11 on Thursday. The stock has a market cap of $74.56 million, a PE ratio of -4.63 and a beta of 1.07. Microbot Medical has a 12-month low of $0.93 and a 12-month high of $2.85. The company has a 50-day moving average of $1.18 and a 200 day moving average of $1.81.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million. On average, sell-side analysts forecast that Microbot Medical will post -0.30 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. CTC Alternative Strategies Ltd. purchased a new stake in shares of Microbot Medical during the 1st quarter worth $28,000. Private Advisor Group LLC acquired a new position in shares of Microbot Medical during the 1st quarter worth about $54,000. Cetera Investment Advisers boosted its position in shares of Microbot Medical by 44.7% during the 1st quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 13,099 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Microbot Medical by 1,688.1% during the first quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock worth $183,000 after purchasing an additional 71,560 shares during the last quarter. Hedge funds and other institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc. (NASDAQ: MBOT) is a medical-device company developing robotic technologies for minimally invasive vascular procedures. Its systems are designed to help physicians remotely control guidewires and catheters during endovascular interventions, with the potential to improve procedural control and reduce clinicians’ exposure to radiation. The company’s primary product candidate is the LIBERTY Endovascular Robotic System, a compact, single-use robotic platform intended to support peripheral and neurovascular procedures.